Novo Nordisk’s Wegovy and copyright, both powered by semaglutide, have revolutionized obesity therapy through unparalleled weight loss effects. In Oct 2024, Novo Nordisk published a research on scientific journal Nature about a novel glucose-sensitive insulin NNC2215 that will lower the